Abstract
Evidence-Based Answer Use of beta-blockers in patients with mild to moderate chronic obstructive pulmonary disease (COPD) does not adversely affect forced expiratory volume in 1 second (FEV1), symptoms, or beta-agonist response (SOR: A, meta-analysis). The effect on mortality is mixed. In COPD populations with high prevalence of heart failure and vascular disease, beta-blockers (predominantly noncardioselective beta-blockers) are associated with decreased mortality (SOR: B, systematic review of cohort studies and single cohort study). In patients with more severe, oxygen-dependent COPD, beta-blockers may be associated with increased mortality (SOR: C, cohort study).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
